Publications by authors named "Christian Scheffold"

Claim this Profile
C
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Joel W Neal, Armando Santoro, Maria Gonzalez-Cao, Farah Louise Lim, Bruno Fang, Christian Scheffold

JTO Clin Res Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Sumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, Cristina Suárez, Martin H Voss, Christian Scheffold

Lancet· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Christian Scheffold

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.
Andrea B Apolo, Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Christian Scheffold

Eur J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Robert J Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Christian Scheffold

Lancet Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Sumanta K Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Christian Scheffold

J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Thomas Powles, Toni K Choueiri, Robert J Motzer, Eric Jonasch, Sumanta Pal, Christian Scheffold

BMC Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Thomas Powles, Toni K Choueiri, Robert J Motzer, Eric Jonasch, Sumanta Pal, Christian Scheffold

BMC Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Daniel J George, Colin Hessel, Susan Halabi, M Dror Michaelson, Olwen Hahn, Christian Scheffold

Oncologist· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
Toni K Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Christian Scheffold

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Toni K Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Christian Scheffold

Eur J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Robert J Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K Choueiri

Br J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
David Cella, Bernard Escudier, Nizar M Tannir, Thomas Powles, Frede Donskov, Christian Scheffold

J Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Patrick Schöffski, Michael Gordon, David C Smith, Razelle Kurzrock, Adil Daud, Christian Scheffold

Eur J Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Toni K Choueiri, Bernard Escudier, Thomas Powles, Nizar M Tannir, Paul N Mainwaring, Christian Scheffold

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Bernard Escudier, Thomas Powles, Paul N Mainwaring, Brian I Rini, Christian Scheffold

N Engl J Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
Ethan Basch, Karen A Autio, Matthew R Smith, Antonia V Bennett, Aaron L Weitzman, Christian Scheffold

Eur Urol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Matthew R Smith, Christopher J Sweeney, Paul G Corn, Dana E Rathkopf, David C Smith, Christian Scheffold

J Clin Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L Kwak, Jose Baselga, Christian Scheffold

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
David C Smith, Matthew R Smith, Christopher Sweeney, Aymen A Elfiky, Christopher Logothetis, Christian Scheffold

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiorgan failure 17 years after initial stone therapy: forgotten ureteral stent in a horseshoe kidney: Part 2.
Gerald Pühse, Hansjürgen Piechota, Christian Scheffold, Stephan Kloska, Lothar Hertle

Eur Urol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiorgan failure 17 years after initial stone therapy: forgotten ureteral stent in a horseshoe kidney.
Gerald Pühse, Hansjürgen Piechota, Christian Scheffold, Stephan Kloska, Lothar Hertle

Eur Urol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Matthias Stelljes, Christiane Specht, Jörn Albring, Sarah Volkmann, Verena Schlösser, Christian Scheffold

Transplantation· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
Guido Bisping, Martin Kropff, Doris Wenning, Britta Dreyer, Sergey Bessonov, Christian Scheffold

Blood· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Matthias Stelljes, Martin Bornhauser, Matthias Kroger, Joerg Beyer, Maria C Sauerland, Christian Scheffold

Blood· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis